STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1346 by analyst upside · 2026-06-27
BVS
Bioventus Inc.
Healthcare · Market Cap $663M · P/E 23.9x
ANALYST PRICE TARGET
+51.3%
implied upside to consensus target
Current Price $9.78
Consensus Target $14.8
Bull Target $16.0
Bear Target $14.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
3
Hold
0
Sell
0
52-Week Low $5.81
52-Week High $11.25
YTD Return +35.6%
FUNDAMENTALS
Market Cap $663M
P/E Ratio (TTM) 23.9x
Forward P/E 10.8x
EPS (TTM) $0.41
PEG Ratio 1.23
Dividend Yield N/A
Revenue (TTM) $576M
Profit Margin 4.9%
52-WEEK RANGE
52-Week Low $5.81
52-Week High $11.25
Current Price $9.78
Bear Target $14.0
Bull Target $16.0
● Now $9.78 ● Target $14.8
TRADING DATA
Avg Volume 574K
YTD Return +35.6%
Analyst Count 5
Consensus Buy
Upside to Target +51.3%
Last Updated 2026-06-27

ANALYST SUMMARY

Bioventus Inc. (BVS) is currently trading at $9.78 with a Wall Street consensus price target of $14.8, implying potential upside of 51.3% over the next 12 months. 5 analysts currently cover BVS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $16.0, while the most cautious has a target of $14.0.

BVS operates in the Healthcare sector with a market capitalisation of $663M. The stock is up 35.6% year-to-date and is currently trading near the upper end of its 52-week range of $5.81 – $11.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BVS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Buy → Buy 2026-06-16 Building track record
Barrington Research — Reiterated
Outperform → Outperform 2026-05-22 Building track record
Barrington Research — Reiterated
Outperform → Outperform 2026-03-06 Building track record
Craig-Hallum — Reiterated
Buy → Buy 2026-03-06 Building track record
Barrington Research ● Initiated
Outperform 2026-02-09 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2025-07-07 40% win rate (10 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2025-03-17 Building track record
JP Morgan ↑ Upgrade
Underweight → Neutral 2024-12-17 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
67
out of 100
Coverage depth
14/30
Consensus clarity
26/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →